Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NGNE
SELLNeurogene Inc. · Healthcare · United States · $696M · Avg Vol: $10M/d
33
StockRankGet insider-trade alerts
Q
27
V
29
M
68
P/E (TTM)
—
ROE
-37.3%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Neurogene Inc. is a clinical-stage biotechnology company pioneering gene therapies for patients with rare neurological diseases. The company leverages its proprietary gene therapy platform and deep scientific expertise to develop transformative treatments, aiming to address the underlying genetic causes of devastating neurological conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0.9M | 0 | — | — | — | — | — |
| EPS | -37.80 | -73.83 | -4.28 | -4.24 | — | -4.54 | -5.31 | -5.46 | — |
| Shares | 12.8M | 12.8M | 14.9M | 15.5M | +20.8% | 20.0M | — | — | — |
| Debt | 4.7M | 16.3M | 14.2M | 11.0M | 32.7% | 9.1M | — | — | — |
| Equity | -145.7M | 186.0M | 310.4M | 264.9M | 19.3% | — | — | — | — |
| Op CF | -52.8M | -51.4M | -70.6M | -77.2M | — | -82.5M | — | — | — |
| Inv CF | -2.2M | 25.6M | -125.3M | 14.0M | — | — | — | — | — |
| Fin CF | 66.5M | 92.5M | 184.1M | 30.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+19.0%
SMA 50SMA 200
Close
$34.62
RSI (14)
44.0
52W High
$43.66
From 52W High
0.8%
SCORE BREAKDOWN
Quality
27
ROIC
-33.2%22.2
ROE
-37.3%23.1
GP/Assets
-28.5%3.6
Op. Margin
0.0%41.3
FCF/Assets
-16.6%22.3
Piotroski
28.8
Int. Cover
-50.0x6.3
D/E Ratio
0.04x73.4
Current Ratio
13.08x90.7
Value
29
P/E (TTM)
—N/A
EV/EBITDA
-3.3x25.0
P/FCF
—N/A
P/B
2.5x52.6
P/S
—N/A
Div Yield
—N/A
Momentum
68
52W High %
79%69.3
RS 6M
81%96.8
SMA 50/200
1.26x92.8
EPS Rev 4W
+2.4%88.1
EPS Rev 12W
+1.6%69.2
EPS Improve
-20%14.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$696M
P/E (Forward)
-6.8x
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NGNE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NGNE | Neurogene Inc.(you) | $696M | 33 | SELL |
| OMER | Omeros Corporation | $709M | 33 | SELL |
| CADL | Candel Therapeutics, Inc. | $700M | 35 | SELL |
| 0KCS.L | OPKO Health, Inc. | $734M | 37 | HOLD |
| GYRE | Gyre Therapeutics, Inc. | $662M | 37 | HOLD |
| IMMX | Immix Biopharma, Inc. | $607M | 31 | SELL |
| TECX | Tectonic Therapeutic, Inc. | $573M | 35 | HOLD |
| CLYM | Climb Bio, Inc. | $735M | 39 | HOLD |
| STTK | Shattuck Labs, Inc. | $710M | 26 | SELL |
| ANRO | Alto Neuroscience, Inc. | $940M | 35 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%